Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Renna

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
United European Gastroenterology Journal|August 11, 2020
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre studyFabio Salvatore Macaluso, Walter Fries, Sara Renna, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 23, 2023
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD studyFabio Salvatore Macaluso, Elvira D'Antonio, Walter Fries, et al.
European Journal of Gastroenterology & Hepatology|June 18, 2025
Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) surveyNicola Pugliese, Cristina Bezzio, Stefano Festa, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 20, 2021
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's diseaseFabio Salvatore Macaluso, Maria Cappello, Federica Crispino, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2018
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysisSara Renna, Filippo Mocciaro, Marco Ventimiglia, et al.
Journal of Gastroenterology and Hepatology|May 20, 2020
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's diseaseFabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, et al.
Journal of Crohn'S & Colitis|October 13, 2025
Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO studyFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.
Inflammatory Bowel Diseases|February 22, 2020
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple SwitchesFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 27, 2025
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort studyFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.
Expert Opinion on Biological Therapy|September 28, 2020
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Fabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
United European Gastroenterology Journal|August 11, 2020
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre studyFabio Salvatore Macaluso, Walter Fries, Sara Renna, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 23, 2023
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD studyFabio Salvatore Macaluso, Elvira D'Antonio, Walter Fries, et al.
European Journal of Gastroenterology & Hepatology|June 18, 2025
Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) surveyNicola Pugliese, Cristina Bezzio, Stefano Festa, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 20, 2021
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's diseaseFabio Salvatore Macaluso, Maria Cappello, Federica Crispino, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2018
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysisSara Renna, Filippo Mocciaro, Marco Ventimiglia, et al.
Journal of Gastroenterology and Hepatology|May 20, 2020
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's diseaseFabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, et al.
Journal of Crohn'S & Colitis|October 13, 2025
Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO studyFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.
Inflammatory Bowel Diseases|February 22, 2020
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple SwitchesFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 27, 2025
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort studyFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.
Expert Opinion on Biological Therapy|September 28, 2020
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Fabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.
Pageof 7